PETS
PetMed Express, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$1.80
−2.70%Year over year
Reported trailing growth
- Revenue
- -19.7%
- EBITDA
- +29.9%
- EBIT
- —
- EPS
- +35.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +2.5%
- EBITDA
- +125.2%
- EPS
- +96.4%
Three-year CAGR
- Revenue
- -11.3%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026